Free tool
FAERS Monitor: Tirosint-Sol
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206977 or its brand name (Tirosint-Sol, Levothyroxine Sodium). Reports on generic versions are filed under their own applications.
Reports
105,950
Serious
71,861
68% of reports
Hospitalization
39,651
Death reported
8,452
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue8,794
- nausea7,563
- diarrhoea6,822
- headache6,722
- dyspnoea6,540
- drug ineffective5,752
- pain5,521
- dizziness5,325
- vomiting4,644
- asthenia4,534
- malaise4,354
- off label use4,266
- fall4,189
- arthralgia4,177
- pruritus3,670
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,043 |
| 2005 | 2,018 |
| 2006 | 2,180 |
| 2007 | 2,761 |
| 2008 | 4,015 |
| 2009 | 3,824 |
| 2010 | 4,310 |
| 2011 | 6,158 |
| 2012 | 6,850 |
| 2013 | 1,453 |
| 2014 | 1,810 |
| 2015 | 2,608 |
| 2016 | 3,443 |
| 2017 | 3,901 |
| 2018 | 4,524 |
| 2019 | 4,399 |
| 2020 | 5,903 |
| 2021 | 6,176 |
| 2022 | 7,733 |
| 2023 | 7,405 |
| 2024 | 7,735 |
| 2025 | 8,648 |
| 2026 | 6,052 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,948,209 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fallSignal | 4,189 | 2.5 | 2.4 | 3,844 |
| astheniaSignal | 4,534 | 2.4 | 2.3 | 3,764 |
| dyspnoeaSignal | 6,540 | 2.3 | 2.3 | 4,926 |
| fatigueSignal | 8,794 | 2.3 | 2.2 | 6,316 |
| headacheSignal | 6,722 | 2.1 | 2.1 | 4,165 |
| dizzinessSignal | 5,325 | 2.1 | 2.1 | 3,240 |
| diarrhoeaSignal | 6,822 | 2.1 | 2.1 | 4,064 |
| arthralgiaSignal | 4,177 | 2.0 | 1.9 | 2,122 |
| malaise | 4,354 | 2.0 | 1.9 | 2,136 |
| vomiting | 4,644 | 2.0 | 1.9 | 2,247 |
| nausea | 7,563 | 1.9 | 1.9 | 3,349 |
| pruritus | 3,670 | 1.9 | 1.8 | 1,589 |
| pain | 5,521 | 1.8 | 1.7 | 1,969 |
| off label use | 4,266 | 1.0 | 0.9 | 5 |
| drug ineffective | 5,752 | 0.9 | 0.8 | 127 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.